抗人類乳癌單源抗體之製備

運用融合瘤技術，本研究室已完成國人乳癌的第一個單源抗體之製備。採用之抗原亦為本研究室自行建立之國人乳癌的第一個細胞株。將2×10^7乳癌細胞，注射入BALB/C小白鼠之腹腔內，間隔二週後追加注射一次，共追加注射兩次；最後一次注射後，取脾臟細胞，於PEG1500作用下，與NS-1骨髓瘤細胞融合，以ELISA方法選取具抗體生產之融合細胞，再經多次篩選。培養出能產製單源抗體之融合瘤細胞注射入BALB/C小白鼠之腹腔內，產生腹水。取出腹水，經Sephacryl S-300層析柱純化後，即得大量之單源抗體IgM，它所認知之抗原亦經測定為乳癌細胞表面之糖脂類（glycolipid）。此對抗國人乳癌之單源抗體在應用於多種人類癌細胞株及國人癌組織之免疫螢光及免疫化學染色法檢測時，發現其具有高度之專一性。由於在國内女性癌症之死亡率中乳癌佔居第二位，且迄無早期診斷乳癌轉移及做為免疫治療之方式，故本研究之成果，應能提供更深入研究，及臨床運用於乳癌之早期診斷及免疫治療等方面。

關鍵字

乳癌；融合瘤技術；單源抗體

並列摘要

A new monoclonal antibody B-14 against human breast carcinoma was produced in our laboratory recently by using the human breast carcinoma cell line BC-M1 which is the first line in Taiwan established also in our laboratory. BALB/c mice were immunized i.p. with 2×10^7 BC-M1 cells. The spllen cells isolated from the immunized animals were fused with NS-1 cells under PEG 1500. The hybrid and productive cells were secreened by ELISA method. After repeat subcloning, the productive hybridoma was kept in massive culture, and then utilized for ascites induction in BALB/c mice. The monoclonal antibody B-14 was purified from ascties by Sephacryl S-300 liquid chromatography. The activity of B-14 was also determined. B-14 is a IgM antibody and recognizes the glycolipid antigens on cell surface of breast carcinoma. The specificity and sensitivity of B-14 were satisfactory. In order to facilitate the breast carcinoma patients in the future, application of this monoclonal antibody in both the academic and the clinical diagnostic and/or therapeutic levels is enthusiastically under evaluation now.

並列關鍵字

Breast carcinoma ； Hybridoma technique ； Monoclonal antibody

國際替代計量

抗人類乳癌單源抗體之製備

未授權

主題瀏覽